Profound Medical Corp. (PRN:CA) Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer Transcript

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

Scan that makes prostate cancer glow reduces need for invasive tests

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile ...

First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...
Fox21Online

New state-of-the-art test identifies aggressive prostate cancer

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm.
UroToday

EAU 2026: Impact of Girentuximab Based Radionuclide Imaging in Patients with RCC on Virtual Tumor Board Decision Making: An Interim Analysis

The 2026 European Association of Urology (EAU) annual meeting featured an advancements in diagnosis and prognosis, and personalized treatment for renal cell carcinoma (RCC) session and a presentation ...